Clinical trial
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With…
NCT00101842 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00101842 |
|---|---|
| Title | Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer |
| Official title | Phase I/II Study of Gemzar and Platinol Followed by Alimta and Gemzar in Patients With Advanced or Metastatic Bladder Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Transitional Cell |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine, Platinol |
| Enrollment | 61 |
| Start date | Dec 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Jan 17, 2005 |
| Last update posted | Aug 29, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: